Four-year follow-up of a phase III study comparing SB3 (trastuzumab biosimilar) and reference trastuzumab in HER2-positive early or locally advanced breast cancer in neoadjuvant setting.

Affiliation auteurs!!!! Error affiliation !!!!
TitreFour-year follow-up of a phase III study comparing SB3 (trastuzumab biosimilar) and reference trastuzumab in HER2-positive early or locally advanced breast cancer in neoadjuvant setting.
Type de publicationJournal Article
Year of Publication2020
AuteursPivot X, Pegram MD, Cortes J, Luftner D, Rugo HS, Lyman GH, Curigliano G, Bondarenko I, Dvorkin M, Yoon YChan, Kim Y, Kim C
JournalJOURNAL OF CLINICAL ONCOLOGY
Volume38
Date PublishedMAY 20
Type of ArticleMeeting Abstract
ISSN0732-183X